Shamburg News · 8-K filed Nov 12, 2026, 9:49 AM EST

MiNK Therapeutics Reports Third Quarter 2026 Results and First Pre-Commercial Product Revenue

INKT · MiNK Therapeutics, Inc.

  • Earnings
  • Materiality: high

MiNK Therapeutics reported a third quarter 2026 net loss of $2.6 million, or $0.50 per share, compared with a net loss of $2.9 million, or $0.65 per share, in the prior-year quarter. The company recognized $0.2 million in pre-commercial product revenue from agenT-797 under its named-patient access program, its first product revenue. MiNK ended the quarter with $7.5 million in cash and cash equivalents.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-457244.

Written from the filing by Shamburg Markets. Figures are as reported by the company.